Follistatin-344 1mg – Research Grade Myostatin Pathway Peptide

Follistatin is a secreted, cysteine-rich glycoprotein originally isolated from ovarian follicular fluid in the late 1980s and characterized as a potent inhibitor of follicle-stimulating-hormone (FSH) release from anterior-pituitary cultures. Follistatin-344 (FS-344) is one of the two principal protein isoforms produced by alternative splicing and translation of the FST gene. The other isoform, FS-315, is the dominant circulating form; FS-344 lacks the C-terminal acidic tail and exhibits a stronger affinity for cell-surface heparan-sulfate proteoglycans, which biases its activity toward tissue surfaces rather than systemic circulation.

In the years following its initial characterization as an FSH-suppressing factor, follistatin was shown to act not on the pituitary directly but by binding and neutralizing activin A — a TGF-β-family ligand that drives pituitary FSH secretion. That mechanism — high-affinity ligand sequestration — was then extended when researchers found that follistatin also binds and neutralizes myostatin (GDF-8), the negative regulator of skeletal-muscle mass identified by Se-Jin Lee's laboratory in 1997. The dual capacity to neutralize both activin A and myostatin placed follistatin at the center of two distinct TGF-β-superfamily research programs: reproductive endocrinology and skeletal-muscle biology.

This page is a research-only educational reference for the FS-344 isoform. It does not describe any therapy, dose, or human-use protocol; FS-344 supplied as a research peptide is intended for laboratory and analytical work only.

Follistatin-344 is the 344-amino-acid protein produced when the FST primary transcript is alternatively spliced to include an exon-6 stop codon, truncating the protein before the C-terminal acidic tail present in FS-315. Both isoforms share an N-terminal domain (FSD) and three follistatin domains (FSD1, FSD2, FSD3), each of which contains an EGF-like subdomain and a Kazal-like subdomain stabilized by conserved disulfide bonds. The follistatin domains form the ligand-binding interface; a follistatin homodimer wraps around an activin (or myostatin) homodimer in a near-complete encirclement that physically blocks the ligand from engaging its type-I and type-II receptors.

The functional difference between FS-344 and FS-315 derives from the C-terminal acidic tail. In FS-315, this acidic tail electrostatically shields a heparin-binding surface in the N-terminal domain, lowering the protein's affinity for cell-surface heparan-sulfate proteoglycans (HSPGs) and biasing FS-315 toward circulation. FS-344 lacks the acidic tail, exposes the heparin-binding surface, and consequently binds HSPGs avidly. The biological consequence is that FS-344 localizes preferentially to tissue surfaces and extracellular matrix, where it acts in a more autocrine/paracrine fashion, whereas FS-315 acts more systemically.

Both isoforms bind activin A with very high affinity (in the picomolar range) and myostatin with affinity in the low-nanomolar range. They also bind other TGF-β-superfamily ligands including GDF-11 and BMP family members, with varying affinities. Follistatin therefore acts as a multi-ligand antagonist within the TGF-β superfamily, with activin and myostatin its best-characterized targets.

Follistatin is not a hormone in the conventional sense and is not a receptor agonist. It is a high-affinity ligand-trap that prevents activins and myostatin from signaling. Effects observed in follistatin-overexpression or follistatin-administration research models reflect derepression of activin- and myostatin-suppressed downstream pathways rather than direct agonism of any receptor.

Follistatin was first purified from porcine ovarian follicular fluid in 1987 by independent groups in Japan and the United States, including the laboratories of Nobuyuki Ueno and Wylie Vale. It was initially named for its ability to suppress FSH secretion from cultured anterior-pituitary cells. Within several years, the mechanism was clarified: follistatin does not act on the pituitary gonadotrope directly but binds and neutralizes activin A, which had been independently characterized as an FSH-releasing factor from the same follicular fluid.

The FST gene was cloned in the late 1980s, and the alternative-splicing relationship producing FS-344 and FS-315 isoforms was characterized shortly thereafter. The structural basis for follistatin's activin-neutralizing activity was elucidated in the early 2000s when X-ray crystal structures of the follistatin-activin complex were solved, revealing the near-complete encirclement of the activin dimer by two follistatin monomers and the structural mechanism by which receptor engagement is blocked.

The myostatin connection emerged after Se-Jin Lee's 1997 discovery of myostatin (GDF-8) as a negative regulator of skeletal-muscle mass. Lee and others showed that follistatin binds myostatin with substantial affinity and that follistatin overexpression in transgenic mice produces dramatic skeletal-muscle hypertrophy reminiscent of the "double-muscled" phenotype observed in myostatin-null animals. That observation placed follistatin firmly within the muscle-biology research literature alongside the broader family of myostatin antagonists.

In the 2000s and 2010s, follistatin gene-therapy approaches were investigated in preclinical models of muscular dystrophy, and exploratory clinical-research programs were conducted in patients with sporadic inclusion body myositis and Becker muscular dystrophy. Those programs are part of the published research record but have not produced an approved therapy. Recombinant follistatin protein (both isoforms) is widely used in academic muscle-biology and reproductive-endocrinology research as a tool reagent for activin/myostatin pathway interrogation.

Follistatin operates within the TGF-β superfamily signaling architecture. TGF-β-family ligands — including activins, myostatin, GDF-11, and BMPs — signal through heteromeric complexes of type-I and type-II serine/threonine kinase receptors, with downstream SMAD-mediated transcriptional output. Activin A binds the type-II receptors ActRIIA/ActRIIB, recruits the type-I receptor ALK4, and activates SMAD2/3 signaling. Myostatin binds ActRIIB (preferentially) and recruits ALK4 or ALK5, also activating SMAD2/3.

Follistatin intercepts these ligands before receptor engagement. The two follistatin monomers wrap around the activin or myostatin dimer in a configuration that occludes both the type-I and type-II receptor binding surfaces. Once bound, the follistatin-ligand complex is internalized and trafficked to lysosomes for degradation, providing a second mechanism — beyond simple sequestration — by which follistatin reduces the bioavailable pool of TGF-β-family ligands.

In skeletal muscle, the consequence of myostatin neutralization is derepression of the satellite-cell proliferation and muscle-fiber-hypertrophy programs that myostatin normally restrains. The published animal-model literature consistently reports increased muscle mass in follistatin-overexpressing models. The activin component contributes additionally: activin A also signals through SMAD2/3 in muscle and reinforces the catabolic program; neutralizing both activin A and myostatin produces a stronger hypertrophic phenotype than neutralizing either alone, an observation that motivated the development of ActRIIB ligand-traps (such as decoy receptors) in addition to follistatin itself.

In the reproductive axis, follistatin's neutralization of activin A reduces FSH release from anterior-pituitary gonadotropes. This is the original physiological context in which follistatin was characterized and remains relevant to reproductive-endocrinology research, where activin/inhibin/follistatin balance governs FSH dynamics across the reproductive cycle.

Beyond muscle and reproduction, follistatin is expressed in many tissues including liver, kidney, pancreas, and brain, and is implicated in the regulation of fibrosis, wound healing, and inflammation through its modulation of TGF-β-family signaling. The breadth of expression and the multiplicity of ligands bound means follistatin sits at a regulatory node with broad tissue-specific consequences.

FS-344 is a 344-residue secreted glycoprotein containing an N-terminal domain (FSD) and three follistatin domains (FSD1, FSD2, FSD3). Each follistatin domain comprises an EGF-like and a Kazal-like subdomain stabilized by conserved disulfide bonds. The mature protein is heavily disulfide-cross-linked and is N-glycosylated at conserved sites. The protein is biologically active as a homodimer when bound to its activin or myostatin ligand, with two follistatin monomers wrapping around one ligand dimer.

The defining structural feature of FS-344 versus FS-315 is the absence of the C-terminal acidic tail. The acidic tail in FS-315 electrostatically masks the heparin-binding surface in the N-terminal domain. FS-344 lacks this masking and therefore binds cell-surface heparan-sulfate proteoglycans with substantially higher affinity, localizing it to tissue surfaces and extracellular matrix.

Research-grade FS-344 supplied for laboratory work is typically produced recombinantly in mammalian (HEK293 or CHO) expression systems to ensure proper folding, disulfide formation, and glycosylation. The molecule is supplied lyophilized and is reconstituted in sterile buffer for in-vitro assay work. Activity is commonly verified by activin-neutralization assays in reporter-cell systems.

In skeletal-muscle biology, FS-344 is used as a tool reagent to interrogate the consequences of activin/myostatin pathway suppression in cell-culture and animal-model studies. Common applications include treatment of cultured myoblasts and myotubes to assess hypertrophic responses, in-vivo administration in rodent models to study muscle mass and fiber-type changes, and use as a positive control in myostatin pathway antagonism studies. The follistatin gene-therapy literature in models of muscular dystrophy (Duchenne, Becker) provides the primary translational context.

In reproductive endocrinology, FS-344 is used to investigate activin-mediated FSH regulation in pituitary cell cultures and in studies of granulosa-cell biology where activin/follistatin balance regulates folliculogenesis. The interplay between activin A, inhibin (a related TGF-β-family heterodimer with opposing activity at type-II receptors), and follistatin is a foundational topic in reproductive-axis research.

Other research domains in which follistatin is studied include hepatic biology (where follistatin modulates activin-driven liver-injury responses), pancreatic biology (follistatin is expressed in pancreatic islets and modulates beta-cell function), and broader fibrosis and wound-healing research where TGF-β-family signaling drives ECM deposition.

Follistatin is also a study tool for the broader question of TGF-β-superfamily ligand selectivity. Comparing follistatin (which binds multiple ligands) with more selective antagonists (such as ActRIIB-Fc decoy receptors, soluble activin receptors, or anti-myostatin antibodies) allows researchers to dissect which downstream effects derive from which specific ligand within the activin/myostatin/GDF-11 family. That comparative work has been particularly important in distinguishing muscle-specific versus systemic effects of pathway blockade.

All applications described here are in-vitro or in-vivo research-model work in academic and commercial research-laboratory settings. Nothing on this page describes a clinical protocol or therapy.

Follistatin sits within a family of activin/myostatin pathway antagonists that share the goal of neutralizing TGF-β-family negative regulators of muscle mass but differ substantially in mechanism, selectivity, and pharmacology.

Follistatin-344 is a recombinant glycoprotein research reagent representing one of the two principal protein isoforms of the FST gene. It is a high-affinity multi-ligand antagonist within the TGF-β superfamily, binding activin A with picomolar affinity and myostatin and GDF-11 with low-nanomolar affinity. The defining structural feature distinguishing FS-344 from FS-315 is the absence of the C-terminal acidic tail, which exposes a heparin-binding surface in the N-terminal domain and biases FS-344 toward tissue-surface localization via heparan-sulfate proteoglycan binding.

In muscle research, FS-344 is used as a tool reagent for myostatin pathway neutralization and produces marked skeletal-muscle hypertrophy in animal-model overexpression studies. In reproductive endocrinology, it is used to interrogate activin-mediated FSH regulation. Across both contexts and the broader TGF-β-superfamily literature, follistatin functions as a ligand trap that derepresses downstream pathways rather than as a direct agonist.

This page is research educational only. FS-344 supplied as a research peptide is intended for laboratory and analytical work; no therapeutic or human-use claims are made.